Skip to Content
  • Previous Rank
    -
  • Revenue 3 Yr Annual Growth Rate
    55%
  • Revenue 3 Yr Growth Rank
    10
  • EPS 3 Yr Annual Growth Rate
    97%
  • EPS 3 Yr Growth Rank
    8
  • Total Return 3 Yr Annual Rate
    -
  • Total Return 3 Yr Rank
    95

Specialty drugmaker Akorn produces generic and branded prescription drugs in hard-to-make dosages like oral liquids and injectables.

Company Information

Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
Location
Lake Forest, Ill.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak-
Years on List1
CEO
Rajat Rai
Websitehttp://www.akorn.com
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Revenue, Net Income

Revenue past four quarters ($M)$1,102
Net Income past four quarters ($M)$183

Growth Rates and Ranks

Revenue 3 Yr Growth Rank10
Revenue 3 Yr Annual Growth Rate55%
EPS 3 Yr Growth Rank8
EPS 3 Yr Annual Growth Rate97%
Total Return 3 Yr Rank95
Total Return 3 Yr Annual Rate-
Beat S&P 500 (9.6%)
no
P/E Ratio22